What’s new in checkpoint inhibition? LAG-3/PD-1 bispecifics, ADC combos, and more

In this week’s VJOncology podcast, we bring you key updates on the evolving landscape of checkpoint inhibition beyond PD-1 and PD-L1 across solid tumors. Join leading experts Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Madrid, Spain, Laurence Buisseret, MD, PhD, Institute Jules Bordet, Brussels, Belgium, and Yuxiang Ma, MD, PhD, Sun Yat-Sen University Cancer Center, Guangzhou, China, as they discuss novel bispecific and bifunctional immunotherapy strategies, first-in-human and early-phase clinical data, and emerging checkpoint inhibitor–ADC combinations shaping treatment paradigms in breast cancer, urothelial carcinoma, and other advanced malignancies.